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Abstract. Coronary Heart Disease (CHD) is a disorder of the cardiovascular system, 
characterized by atherosclerotic lesions. Inflammation is a strong predictor for coronary 
heart disease. High sensitivity C-Reactive Protein (hs-CRP) is an important biomarker, 
synthesized in the liver, can predict the severity of CHD. If the hs-CRP level is found to be 
low 3 mg / L, a person has the potential for severe vascular risk. Therefore, hs-CRP can be 
used as a predictor of primary CHD prevention, especially if the hs-CRP level is still low. 
Keyword: Biomarker, hs-CRP, CHD 
Abstrak. Penyakit Jantung Koroner (PJK) adalah gangguan sistem kardiovaskular, 
ditandai oleh lesi aterosklerotik. Peradangan adalah prediktor kuat untuk penyakit jantung 
koroner. High sensitivity C-Reactive Protein (hs-CRP) adalah biomarker penting, disintesis 
di hati, dapat memprediksi tingkat keparahan PJK. Jika level hs-CRP ditemukan rendah < 
1 mg/L, mengisaratkan bahwa peradangan sistemik atau arteri koroner masih rendah dan 
risiko aterosklerotik masih rendah. Jika kadar hs-CRP berada di antara 1 dan 3 mg/L 
mengindikasikan risko vascular sedang, dan jika kadar hs-CRP > 3 mg/L, sesorang sangat 
potensial berisiko vaskular yang parah. Oleh karen itulah hs-CRP bisa digunakan sebagai 
prediktor pencegahan PJK primer, terutama jika level hs-CRP masih rendah. 
Kata Kunci: : Biomarker, hs-CRP,  PJK 
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1. Introduction 
Cardiovascular disease (CVD) is a group of heart and blood vessel disorders, including coronary 
heart disease, vascular disease that supplies oxygen and blood to the heart muscle; 
cerebrovascular disease, vascular disease that supplies oxygen and blood to the brain; peripheral 
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arterial disease, vascular disease that supplies oxygen and blood to the arms and legs; rheumatic 
heart disease, damage to the heart muscle and heart valves due to rheumatic fever, caused by 
streptococcal bacteria; heart disease - malformation of the structure of the heart from birth. Of 
the 56.9 million deaths worldwide in 2016, more than half (54%) were caused by ischemic heart 
disease and stroke. This disease is one of the leading causes of death globally in the last 15 
years. Indonesia's 2014 Sample Registration System (SRS) shows that CHD is the second 
highest cause of death after stroke, which is 12.9% of all the highest causes of death in 
Indonesia [1, 2]. 
Coronary heart disease is one of the most common diseases of the cardiovascular system, 
characterized by atherosclerotic lesions. Atherosclerotic vascular processes are multifactorial. 
One factor is the inflammatory process. Platelet to lymphocyte ratio (PRL) is a marker that 
predicts atherosclerotic coronary load [10]. Handling of CVD, in this case, CHD is highly 
dependent on the ability to identify individuals who are at high risk before the disease 
progresses. Therefore, it is necessary to observe an accurate level of risk. Increased knowledge 
regarding the role of biomarkers is increasingly important for identifying and predicting 
cardiovascular events. Biomarkers play an important role in defining, prognosis, and decision 
making regarding the management of cardiovascular events. This review is aimed at biomarkers 
of high sensitivity C-Reactive Protein (hs-CRP) inflammation to predict CHD and death. CRP is 
one of the important biomarkers that reflects various aspects of the development of 
atherosclerosis [7]. 
This inexpensive and simple approach to evaluating coronary heart disease has been approved 
by the Centers for Disease Control and Prevention and by the American Heart Association 
(CDC-AHA). When measured by the hs-CRP test, CRP levels less than 1, 1 to 3, and greater 
than 3 mg/L can distinguish between individuals at low, moderate, and high risk of heart attack 
and stroke in the future. front. However, it is important to understand that CRP testing does not 
mean replacing cholesterol evaluation. Instead, the CRP test must be used in conjunction with 
cholesterol and other traditional risk factors to determine an individual's risk, possibly having 
CHD. Evidence also shows that individuals with high CRP levels are at higher risk of 
developing diabetes. This article is intended to discuss the impact of increasing CRP levels and 
the clinical use of CRP [9]. 
2.  Coronary heart disease 
CHD is a condition caused by the presence of atheromatous plaques the coronary arteries that 
cause an obstruction and gradually narrows one or more coronary arteries in epicardium [3]. 
This condition will cause an imbalance between myocardial oxygen supply and demand causing 
myocardial ischaemia/hypoxia and accumulation of residual metabolites. Symptoms will appear 
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with increased activity, but can also occur spontaneously and are characterized by symptoms of 
discomfort in the chest transiently (angina pectoris) [4, 5]. 
CHD is a chronic inflammatory disease that occurs gradually, influenced by environmental 
exposure, lifestyle factors, and genetic factors that can be described from risk factors, 
inflammatory biomarkers, and metabolic status [6]. Experimental and clinical evidence shows 
that since 1990 has established the inflammatory process as an important contributor to 
atherogenesis and susceptibility of atherosclerotic lesions to rupture or lesions. Based on this 
evidence, markers of inflammatory proteins have been studied as non-invasive indicators of 
underlying atherosclerosis in apparently healthy individuals. The most widely studied biomarker 
of inflammation in cardiovascular disease is serum CRP, through hs-CRP testing [7]. 
Inflammation is a strong predictor for coronary heart disease. Among the important 
inflammatory biomarkers intensively studied are hs-CRP, which is an acute-phase reactant, 
interleukin-6 (IL-6) and tumour necrosis factor-alpha (TNF-α), both inflammatory cytokines 
and intercellular adhesion molecule -1 ( ICAM-1), which is a marker of endothelial function. 
CRP is produced by hepatocytes, the regulation by IL-6 and TNF-α and is found in endothelium 
atherosclerotic plaques, smooth muscle cells, macrophages, and adipocytes. CRP affects the 
endothelium by changing the bioavailability of nitric oxide, resulting in an increase in ICAM-1 
[8]. 
3. Diagnosis of Coronary Heart Disease 
The classic clinical manifestation of CHD is angina pectoris, which is a clinical syndrome of 
chest pain that arises when performing activities due to myocardial ischemia. This shows that 
there has been > 70% narrowing of the coronary arteries. Angina pectoris can be stable angina 
pectoris (SAP, stable angina) and this condition usually develops to become more severe and 
cause Acute Coronary Syndrome (ACS) or known as sudden heart attack which can cause 
death. 
Some important definitions related to CHD are Stable Angina Pectoris (SAP) is a clinical 
syndrome characterized by chest, jaw, shoulder, back or arm pain, which is usually triggered by 
physical work or emotional stress; this complaint can subside when rested or if given 
nitroglycerin under the tongue. Angina Prinzmetal is chest pain caused by coronary artery 
spasm, often arises at rest, not related to physical activity and sometimes is periodic (at the same 
time every day). While Acute Coronary Syndrome (ACS) is a clinical syndrome that has the 
same pathophysiological basis, namely the presence of erosion, fissure, or rupture of atheroma 
plaque, causing intravascular thrombosis which causes an imbalance of myocardial oxygen 
supply and demand. Included in the ACS are unstable angina pectoris (UPS, unstable angina): 
characterized by sudden and more severe chest pain, and longer attacks (more than 20 minutes) 
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and more frequent and acute myocardial infarction (AMI) is angina pain in acute heart 
infarction is generally more severe and longer (30 minutes or more). However, heart infarction 
can occur without chest pain (20 to 25%). AMI can be in the form of non-Q waves MI 
(NSTEMI) and Q-waves MI (STEMI) which can be observed on ECG records [11]. 
Patients with suspected CHD can be diagnosed by invasive and non-invasive examinations. In 
patients with a diagnosis of stable CHD, especially non-invasive examination needs to be done 
by laboratory examination, ECG at rest, echocardiography and chest X-ray. Laboratory tests 
include total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein 
(HDL) cholesterol, triglycerides, serum creatinine (glomerular filtration rate) and fasting blood 
sugar levels [14]. ECG examination is normal in some stable CHD patients. A normal ECG 
shows that left ventricular function is still good. An abnormal ECG imaging that can be found is 
non-specific ST-T wave changes with or without pathological Q-waves. In patients proven to 
have coronary lesions, ST-T segment abnormalities are associated with disease severity. Other 
non-invasive tests that can be performed are cardiac training, myocardial perfusion imaging, 
stress echocardiography, cardiac CT-scans, and cardiac magnetic resonance imaging [9, 12, 13]. 
Percutaneous coronary intervention (PCI) is one of the most important methods for the 
treatment of severe CHD, with in-stent restenosis (ISR) which will affect long-term curative 
effects. Selection of Coronary angiography (CAG) is the best test for the diagnosis of ISR after 
PCI. However, the CAG examination method is invasive, which requires time and ability to 
assess the severity of coronary anatomy. Coronary angiography has 2 main objectives, namely 
to assess the risk of cardiovascular events and death of the patient and help determine the choice 
of revascularization therapy [12, 13]. Biomarker indicators for predicting ISR have become the 
main focus in the academic and research fields. It was reported that several indicators in serum, 
in addition to traditional risk factors (for example, age, sex, blood pressure, blood lipids, etc.), 
can also be used as independent risk factors to assess CHD and are closely related to 
cardiovascular events. hs-CRP is a marker of inflammation, which is synthesized by the liver 
which can be used to predict the risk of cardiovascular disease especially CHD [12, 14]. 
4. Biomarkers of Coronary Heart Disease (CHD) 
Biomarkers are broad subcategories of biological markers that can be measured and reproduced. 
In a broad sense, biomarkers are specific compounds that are measured and evaluated 
objectively as indications of normal biological processes, pathogenic processes, or 
pharmacological responses to therapeutic interventions. A useful biomarker must meet the 
following criteria: (1) accuracy: that is, the ability to identify individuals at risk; (2) reliability: 
that is, the stability of the results when repeated; and (3) therapeutic impact with early 
intervention [8]. 
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Biomarkers are often used to detect cardiovascular-related diseases, because certain biomarkers 
can provide valuable information regarding diagnosis, treatment, identification of individuals at 
risk of heart failure, and potentially pathogenesis that causes cardiovascular disease. For 
biomarkers to be clinically useful, biomarkers must meet several criteria, namely biomarker 
levels must be accurately assessed using widely available and cost-effective methods, 
biomarkers must provide additional information from tests that have been carried out such as 
MRIs, and biomarker information must assist in taking medical decision. A number of enzymes, 
hormones, markers of heart stress or necrosis, cytokines, and other biological agents have been 
examined as biomarkers for heart failure. Although biomarkers are discussed in this review by 
category (for example those related to heart damage or inflammation), in fact many of these 
biomarkers interact or are related to each other which shows that the combination of biomarkers 
tends to provide the best risk assessment for cardiovascular disease [15]. 
Inflammation is important in the pathogenesis of many conditions that lead to heart failure. 
Traditionally, inflammatory biomarkers have been considered risk markers rather than risk 
factors because the role of these biomarkers in the pathogenesis of the disease is not always 
clear. Many inflammatory biomarkers found in the circulation, such as CRP, IL-6 and serum 
amyloid A protein (SAA), are part of the acute phase response that arises and responds to the 
liver and although it is strongly associated with the disease, it may simply be a conclusion 
inflammation. In clinical studies, inflammatory mediators in coronary arteries have been used to 
predict the progression of coronary artery disease to heart failure similar to biomarkers of injury 
and / or neuro-hormones. In animal studies and clinical observations, inflammatory biomarkers 
appear to be indicative of left ventricular dysfunction, increased edema, and induced endothelial 
dysfunction and cardiomyocyte apoptosis, and other damaging effects. A long-term study in 
myocarditis patients reveals that inflammation is the best predictor of predicting progression to 
heart failure after acute myocarditis. Viruses such as CVB3, adenovirus, parvovirus B19 and 
hepatitis C virus are often detected on patients' myocardial biopsy. Antiviral treatments such as 
interferon-reducing inflammation and heart failure in animal models and patients, this implies 
that viral infections are an important cause of myocarditis cases leading to heart failure. 
Inflammation is closely related to the etiology of the development of heart failure, and not only 
that, but also the consequences of chronic heart failure that have an increased concentration of 
inflammatory mediators, other than as a clue to a poor prognosis. There is evidence that cellular 
damage and auto / antibody mediated contribute to the development of dilated cardiomyopathy 
(DCM) and heart failure after myocarditis [15]. 
There are several biomarkers associated with CHD, stroke, or both, but only a few are tested for 
their effect on predicting risk. The most frequently studied biomarker is hs-CRP. Other 
biomarkers that seem promising include lipoprotein-associated phospholipase A2 (LpPLA2) 
and amino-terminal pro-B-type natriuretic peptide (NT-proBNP). CRP is a non-specific marker 
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of inflammation. CRP was initially tested in conjunction with cardiovascular disease because 
scientists are aware of the role of inflammation in the pathogenesis of atherosclerosis. In several 
studies, scientists reported an association between hs-CRP levels and the incidence of CHD, 
stroke, or both [16]. 
5. High sensitivity C-reactive protein (hs-CRP) 
CRP was first described by William Tillet and Thomas Francis at the Rockefeller Institute in 
1930. They extracted proteins from the serum of patients suffering from pneumonia 
pneumococcus which would form precipitation with C polysaccharides from cell walls. 
Pneumococcus. Because the reaction between proteins and polysaccharides causes precipitation, 
this protein is named C-Reactive Protein [17]. 
 
Figure 1. Mechanism of the relationship between CRP and cardiovascular events [20]. 
The potential mechanism of the relationship between CRP and cardiovascular events is due to 
risk factors for atherosclerosis which encourage atherogenesis and vascular inflammation by 
releasing cytokines such as interleukin 6 (IL-6), Interleukin-1 (IL-1), and Tumor Necrosis 
Factor-α (TNF-α) ) from activated leukocytes. Furthermore, IL-6 will stimulate the release of 
CRP from the liver. On the other hand, adipose tissue directly promotes atherosclerosis and is 
also a major source of IL-6 which increases CRP levels. These events occur in parallel without a 
direct relationship between CRP and vascular disease. The mechanism of association between 
CRP and cardiovascular events can be seen in Figure 1 [20]. 
Recent research has shown that CRP conformations adopt two different forms, namely the 
pentamer isoform (pCRP) and the monomer isoform (mCRP), which have different antigenic, 
electrophoretic, and biological functions. Although pCRP is the main form detected in serum 
and is a very stable molecule, this evidence shows that the conformational subunits of pCRP can 
be separated, both in vitro and in vivo into a single unit of mCRP. On the other hand, free 
mCRP synthesis can be a major source of pCRP formation. Both forms of CRP isoform are 
involved in several processes: pCRP produces an inflammatory response that binds to 
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phosphatidylcholine on the outside of LDLox and apoptotic cell surfaces, while mCRP plays a 
role in the formation of aggregations that lead to complications of atherothrombosis [19]. 
Furthermore, the activation of this pathway contributes to the formation and development of 
atherosclerosis which will induce arterial smooth muscle cell proliferation and increase 
synthesis of IL-8 secretion and monocyte chemotactic protein (MCP-1). CRP also participates 
in activating Nuclear Factor kappa B (NF-𝜅B), this transcription factor is present in cells and 
provides a fast response involved in immune and inflammatory reactions, thereby increasing the 
production of cytokines, chemokines, adhesion molecules, growth factors, and immuno 
receptors in several types of cells in atherosclerotic plaque. CRP will inhibit the affinity of 
compounds derived from factor H protein, so that the CRP isoform binds to the factor H protein 
as well as binds to calcium. In contrast, CFHR4 can bind pCRP through a calcium dependent 
mechanism. These proteins can facilitate the formation of CRP on the surface of necrotic cells, 
acting as a regulator that dissolves from the alternative pathway of the complement activation 
system. Excessive activity from this pathway will lead to the amount of C3a and C5a 
circulating, resulting in the potential for strong anaphylatoxins involved in the local 
inflammatory response. In vitro studies have shown that the expression of CR3 and CR5a in 
atherosclerotic arteries is the cause of plaque in coronary arteries. CR3 and CR5a support the 
occurrence of chemotaxis in monocytes, mast cells, and lymphocytes, adhesion of endothelial 
molecules, and in turn increase TNF and IL-1 release, in addition to specific reactive oxygen 
production based on location. 
 
Figure 2. The key role of c-reactive protein (CRP) in atherosclerosis. (a) Activation of the 
complement system. (b) Activation of different receptors in inflammatory cells. (c) Changes in 
the shape of the extracellular matrix. (d) Interaction with lipoproteins. (e) Impaired synthesis of 
Nitric oxide. (f) Cell recruitment [19].  
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(b) Interaction with cellular receptors. The Fc𝛾R family is the main target of CRP which plays a 
role in the process of controlling activation, proliferation, phagocytosis, degranulation, and 
cytokine secretion, thereby regulating the local inflammatory process, as occurs in the formation 
of atherosclerotic plaque. The two forms of the CRP isoform can bind to Fc𝛾RI, Fc𝛾RIIA, and 
Fc𝛾RIII, thus encouraging conformational changes in the structure which in turn triggers an 
intracellular signaling cascade. In general, this cascade begins with sequential activation of 
tyrosine protein kinase (TPK) which phosphorylates tyrosine residues followed by activation of 
tyrosine kinase compounds which will produce multiple signaling molecules, including other 
kinases such as protein kinase C (PKC), extracellular signal regulating kinases (ERK) , 
mitogen-activating protein kinases (MAPK), and phosphatidyl inositol-3-kinase (PI3K), and 
phospholipase C (PLC), intracellular adaptation molecules, and second messengers such as 
calcium (Ca), diacylglycerol (DAG), and inositol-3- phosphate (I3P). The key role of CRP in 
atherosclerosis can be seen in figure 2. 
(c) Changes in the shape of the extracellular matrix through selection, modulation, and 
activation of immune cells. pCRP is a direct regulator of endothelial cell activation and 
dysfunction, by inducing intracellular cell adhesion, vascular E-selectin, and monocyte 
chemoattractant protein-1 (MCP-1) which causes chemotaxis and binding of endothelial cell 
monocytes during the early stages of atherogenesis. In addition, CRP suppresses changes in the 
form of monocytes to the proinflammatory M1 phenotype, mediated by the Fc𝛾 receptor and the 
NF-jalurB pathway, and forces a change in the cytokine secretion pattern in M2 macrophages 
towards the proinflammatory phenotype as in M1. In vitro studies show that when CRP 
concentrations <10 μg / mL there will be decreased prostaglandin F-1α synthesis, prostacyclin 
metabolites that regulate endothelial vasodilation, platelet aggregation, and smooth muscle cell 
proliferation. In addition, CRP also increases the expression of angiotensin 1 receptors (R-AT1) 
through MAPK and NFκB resulting in proliferation, deformation and migration of smooth 
muscle cells in atherosclerotic lesions [19]. 
(d) Activation of the metalloproteinase enzyme. Metalloproteinases are proteolytic enzymes 
responsible for reshaping extracellular matrix (ECM), which are involved in atherogenesis and 
rupture of atherosclerotic plaque. 
(e) Synthesis of nitric oxide. (NO) is a simple gas produced by the enzyme NO-synthase 
(eNOS). NO is widely distributed in several tissues, especially in endothelial cells, NO plays a 
role in the process of vasodilation, antioxidants, and antithrombotic effects. In vitro and in vivo 
studies show that CRP can interfere with NO synthesis by inhibiting endothelial eNOS through 
various pathways, all of which cause endothelial dysfunction. 
(f). Lipoprotein. mCRP selectively binds to low density lipoproteins (LDL) and, in small 
proportions, binds to very low density lipoproteins (VLDL). Whereas pCRP interacts mainly 
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with immunopatogen lipoproteins that are highly immunogenic, such as LDL-ox, enzymatic 
LDL (E-LDL) and minimally modified LDL (mmLDL). The acidity of the microenvironment at 
the site of inflammation plays a key role in binding CRP to lipoproteins, because the binding 
site for LDL-ox only occurs after modification in CRP structures that are triggered in an acidic 
atmosphere. In vivo testing shows that CRP not only increases LDL-ox absorption, but also 
stimulates the accumulation of cholesterol esters in human macrophages [19]. 
Some drugs like Colchicine and statins are reported to be able to inhibit its production. CRP has 
a long half-life in plasma and is known to be a mediator and marker of atherothrombotic 
disease. CRP levels tend to increase significantly 6-8 hours after initial release, maximum at 24-
48 hours, with a half-life of around 19 hours. The concentration of CRP in circulation is mainly 
determined by the rate of synthesis. A research report, has measured CRP in healthy women and 
men, to see the relationship of CRP and cardiovascular events from other cardiovascular risk 
factors. In the meta-analysis, which included more than 160,000 subjects, nearly 28,000 
incidents of cardiovascular events; each increase in standard deviation of values is associated 
with an increase in the relative risk of 1.37 for CAD (95% CI: 1.27-1.48) and 1.55 (95% CI: 
1.37-1.76) for mortality caused by CVD . In addition, in patients undergoing percutaneous 
coronary intervention (PCI), higher CRP levels at the time of examination are predictors of 10-
year mortality due to myocardial infarction (MI) [8, 20]. 
Based on the evidence obtained, the European Society of Cardiology (ESC) and the CDC-AHA 
recommend a grouping and state that hs-CRP can be measured as part of a moderate or 
moderate cardiovascular risk assessment. As such, interpretations of the hs-CRP result are 
elaborated with: levels < 1 mg/L are desirable levels and reflect lower systemic inflammatory 
status and lower atherosclerotic risk; levels between 1 to 3 mg/L indicate moderate vascular 
risk; levels of > 3 mg/L indicate a higher vascular risk in the context of other risk factors and a 
value of > 10 mg/L may reflect a transient infectious process or other acute phase response, so it 
must be repeated two to three weeks later. Despite having a direct relationship with 
cardiovascular events, recent research has confirmed that CRP values are predictors of 
cardiovascular events, CRP is not a causative factor for CVD [8, 18]. 
However, the most important use of CRP today is primary prevention, namely in detecting risks 
among individuals who are not yet known to have a problem. Individuals with high CRP levels 
have a risk of about 2 to 3 times higher than individuals who have low CRP levels. Because 
CRP is an "acute phase reactant" and increases during major trauma and infections. However, 
several studies have shown that the role of CRP, when properly measured by high sensitivity 
tests in stable individuals, is specific enough to predict future cardiovascular events. In a recent 
study, it was produced that an increase in CRP levels was associated with an 8-fold increase in 
cardiovascular mortality, but it did not have a predictive value of death from other causes. CRP 
can also be a predictor of heart attack and stroke, but not in individuals with cancer or other 
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major disorders. Thus, an ever-increasing CRP level is an indication of the risk of heart disease 
and accelerated atherosclerosis [9]. 
6. Conclusion 
Based on research evidence that there is a hs-CRP biomarker in CHD to date is a predictor in 
primary prevention of disease. Individuals with high CRP levels have a risk of about 2 to 3 
times higher than individuals who have low CRP levels in CVD. 
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